1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer
  4. >>Immuno-oncology

Keytruda To Enjoy First-To-Market Advantage As TNBC Approval Now More Likely

 
• By Alaric DeArment

Merck & Co. unveiled event-free survival data for Keytruda in triple-negative breast cancer, following a failure earlier this year to gain approval on a surrogate endpoint.

Doctor with Mammography - Image
Keytruda unveils EFS data for Keytruda in triple-negative breast cancer and seeks FDA approval • Source: Shutterstock

Merck & Co., Inc. has bolstered its chances of winning US Food and Drug Administration approval for Keytruda (pembrolizumab) in neoadjuvant triple-negative breast cancer (TNBC) with Phase III trial data showing a benefit in event-free survival, meaning that it will likely benefit from a first-to-market advantage in the setting. But the data do not support the use of a surrogate endpoint the company unsuccessfully tried to use before.

The Kenilworth, NJ-based firm reported in May that the KEYNOTE-522 study testing Keytruda and chemotherapy before surgical resection followed by...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immuno-oncology

More from Anticancer

Enliven Raises $230m To Fund Scemblix Leukemia Challenger

 
• By Andrew McConaghie

The company believes its drug could eventually displace Novartis’s Scemblix in first-line chronic myeloid leukemia treatment, but for now is preparing for a second-/third-line pivotal study.

BMS’s Breyanzi Stands To Further Expand Broad Lymphoma Coverage

 
• By Alaric DeArment

The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.